Doximity (NYSE:DOCS – Get Free Report) and OBOOK (NASDAQ:OWLS – Get Free Report) are both services companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Analyst Recommendations This is a summary of current ratings for Doximity and OBOOK, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Doximity 3 13 6 2 2.29 OBOOK 1 0 1 0 2.00 Doximity presently has a consensus target price of $29.33, suggesting a potential upside of 39.73%. OBOOK has a consensus target price of $11.00, suggesting a potential upside of 101.83%. Given OBOOK’s higher possible upside, analysts clearly believe OBOOK is more favorable than Doximity.
Profitability This table compares Doximity and OBOOK’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Doximity 30.40% 20.40% 17.43% OBOOK N/A N/A N/A Institutional and Insider Ownership 87.2% of Doximity shares are owned by institutional investors. 31.8% of Doximity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation This table compares Doximity and OBOOK”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86 million 5.95 $196.05 million $0.99 21.21 OBOOK $7.86 million 61.25 -$31.85 million N/A N/A Doximity has higher revenue and earnings than OBOOK.
Summary Doximity beats OBOOK on 10 of the 12 factors compared between the two stocks.
About Doximity (Get Free Report)
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
About OBOOK (Get Free Report)
Our mission is to use blockchain technology to provide businesses with more reliable and transparent data management, to reinvent global flow of funds for businesses and consumers and to lead the digital transformation of business operations. We believe in the power of blockchain technology and have focused on leveraging it to optimize and in some cases transform the way enterprises operate. Established in 2010 in Taiwan, we operate as the OwlTing Group and have delivered solutions to various industries and are expanding actively into multiple markets including the United States, Japan, Singapore, Hong Kong, Malaysia and Thailand, as well as jurisdictions in South America and the EU. Through our e-commerce, hospitality and payments offerings, we are committed to serving businesses and individuals whose commercial activities involve cross-border transactions. From our earliest days with our product OwlTing Market™, our e-commerce platform that was designed to connect local Taiwanese farmers and merchants with their customers, we have worked closely with the merchants on our platform and come to understand their business pain points. Our OwlTing Blockchain Services™ emerged from such business understanding, and we have aimed to build a blockchain traceability solution that empowers organic farmers with better transparency of their business and operations, which can be extended to other use cases. By building our expertise in blockchain ledger transaction models, we concluded that the prevention of double spending with the use of timestamps and proof of work could also be utilized in the hospitality industry, which faces the need to address double-booking problems. We thus expanded into the hospitality sector in 2018 by offering innovative solutions to hotels and other hospitality industry customers through our platforms, including the OwlNest™ hotel property management system, or PMS, that leverages blockchain technology to prevent double bookings. We also launched the OwlJourney™, an online travel agency, or OTA, platform that benefits from accurate real-time inventory data from integration with OwlNest’s inventory system, to empower travel service providers with optimized efficiencies. In addition, our OwlTing Experiences™, also an OTA, focuses on offering curated local activity and tour options for lodging guests, enriching their travel experiences beyond accommodations. As we further developed our presence in the hospitality industry, we also gained a first-hand understanding of the challenges of cross-border payments faced by our hospitality clients. We saw the issues faced by our hospitality clients and their two most prominent pain points in the payment process: high processing costs from cross-border transactions and delayed settlement from the payers, including large OTAs. In response, we launched OwlPay™ in 2023 intending to enable businesses in the hospitality sector and beyond to use stablecoins and/or fiat currency in payouts to global suppliers. OwlPay is an application programming interface, or API, based payment suite with secure, real-time and cost-effective one-stop payment solutions covering a range of services from payment gateway to business payout. Using blockchain technology and developer-friendly APIs for integration, OwlPay aims to payments for both businesses and consumers. OwlPay is a full-stack payment service suite that supports multiple payout settlement routes, not only in fiat currency but also in stablecoin USD Coin (“USDC”) backed by U.S. dollar-denominated assets, through various product offerings. We currently offer various solutions for both platform solutions that provide user interfaces to our end users and infrastructure solutions that support third-party providers, through OwlPay Payment, OwlPay Wallet Pro and OwlPay Harbor within the OwlPay suite. OwlPay Payment provides user interfaces that offer services ranging from payment gateway to various payout solutions in stablecoin and fiat currencies. OwlPay Wallet Pro is a platform product that provides a hosted wallet for business customers and an unhosted wallet for individual users, supporting stablecoin on/off-ramp services and enabling both business and individual customers to receive and send money both domestically and internationally within minutes, with stablecoins over the public blockchain ledgers Ethereum, Avalanche, Polygon, Optimism, Arbitrum and Stellar. In addition, OwlPay Wallet Pro recently introduced a digital gift card service in the U.S., allowing users to purchase and redeem gift cards directly with USDC, thereby extending the everyday utility of stablecoins in retail and consumer payments. We also provide an infrastructure solution: OwlPay Harbor—our proprietary API packages—provides the functionalities of payment gateway collection of customers fund via stablecoins, on/off-ramp between fiat currencies and stablecoins, cross-chain transactions between USDC across different blockchains, and payout capabilities, empowering third-party wallet providers, financial institutions, and platform operators requiring cross-border payment solutions to offer stablecoin-based payment gateways, on/off-ramp services, cross-chain transactions, and payouts to their end users by leveraging our infrastructure. We currently provide these API packages across multiple blockchains, including EVM-compatible networks, the Solana network, and the Stellar network, where we serve as a “Stellar Anchor”. We also plan to provide Wallet-as-a-Service (WaaS), allowing enterprises to customize and deploy wallets for their end users. For our end customers holding a wallet with our OwlPay Wallet Pro, we provide the on/off-ramp services to facilitate conversion between USDCs and U.S. dollars, both directly interfacing our products and through our third-party collaborators and service providers, MoneyGram and MoonPay. For business customers that wish to leverage USDC, we offer on/off-ramping services via wire transfers and automated clearing houses (“ACH”). For individual customers, we offer on/off-ramping services via wire transfers and ACH, as well as via cash and credit card leveraging our collaborations with MoneyGram and MoonPay, respectively. We plan to further expand our on/off-ramping capabilities via debit cards using VISA Direct. Such conversion services are also available to customers of third-party wallet providers or financial institutions using OwlPay Harbor, our proprietary API package that enables third-party users to access our conversion capabilities, between fiat currencies and stablecoins, as well as between USDC across different blockchains (which also integrates stablecoin-based payment gateway solutions and payout capabilities). All transactions are within standard security and compliance infrastructure on par with a traditional financial institution. To make transactions more convenient for our OwlPay Wallet Pro customers on supported blockchains, we handle the payment of the gas fees (which are transaction fees paid for executing transactions on a blockchain network, typically paid in the digital asset native to such blockchain network) incurred on these blockchains on behalf of our OwlPay Wallet Pro customers for certain types of customers and transactions, so that these customers do not need to hold the native digital assets of the transaction chain. We currently support OwlPay Wallet Pro’s customers to send, receive and hold USDC, EURC, ZUSD, and GYEN and the conversion between USD and USDC. Additionally, for individual customers, we also support sending, receiving and holding native digital assets. OwlPay Wallet Pro recently introduced a digital gift card service in the U.S., allowing users to purchase and redeem gift cards directly with USDC, thereby extending the everyday utility of stablecoins in retail and consumer payments. OwlPay’s customers are currently able to access various fiat currency and USDC payment options and perform these payment transactions within OwlPay suite. We plan to expand OwlPay Wallet Pro services to support more blockchains, including Base, and plan to diversify our stablecoin offering to enable a broader set of conversion corridors between fiat currencies and stablecoins, as well as to facilitate foreign exchange transactions using stablecoins in the future. We have also rolled out our OwlPay Harbor services to other participants in the digital asset economy and payment industry, including serving as a “Stellar Anchor” for on/off-ramping USDC on Stellar to third parties on the Stellar Network and supporting EVM-compatible blockchains and Solana. OwlPay is designed to simplify backend financial operations and cross-border transactions. For potential business clients without in-house technical teams to support system integration but requiring payment gateway and cross-border payout services, we offer OwlPay Payment—an user interface solution that seamlessly connects with their bank accounts/wallets, facilitating vendor and order management, mass payouts, real-time exchanges and automated payment processes using fiat currency and USDC. The payout transactions are signed using hardware security module technology, a specialized security device used to manage, process and store digital keys securely, in order to ensure cryptographic operations are performed within a tamper-resistant environment. All of these features enhance the payment experience for businesses, especially SMEs that have limited scale of operations but still require efficient cross-border payment solutions. Beyond business clients, we expect to further develop and release services for individual customers that would integrate payment services offered by card networks, such as VISA Direct, to provide our individual customers a convenient way to send funds from a bank or card account to another party’s card or bank account within the same card network. Within the OwlPay suite, our customers can access various fiat currency and USDC payment options and seamlessly perform transactions through different solutions, and we believe we are an early mover to provide the one-stop service framework which enables businesses to collect payments from end-users and make payments to vendors, with the flexibility to settle transactions in either fiat currency or USDC and enables individuals a simpler, more convenient and faster way to perform cross-border transactions and remittances. According to CB Insights’ latest Stablecoin Market Map, OwlTing is ranked among the top 2 global players in the “Enterprise & B2B” category, earning a high Mosaic score of 832—underscoring its leadership in blockchain-powered financial infrastructure for businesses. OwlPay for its business customers supports B2B stablecoin transactions via a hosted wallet infrastructure and a comprehensive suite of services, including stablecoin payment gateway services, on/off-ramp capabilities, cross-chain transfers and payout services. These services enable key use cases such as e-commerce payments, cross-border remittances, payroll, and treasury management. The Mosaic score—CB Insights’ proprietary metric evaluating market opportunity, momentum, and financial strength—highlights OwlTing’s strong market positioning and growth potential in the enterprise stablecoin ecosystem. OwlPay continues to build multi-jurisdictional capabilities and aims to expand its service offerings internationally. For example, we currently hold money transmitter licenses, or MTLs, in 35 states in the United States and the Virtual Asset Service Provider, or VASP, registration in Poland, and the Electronic Payment Instrument Service Provider, or EPISP, registration in Japan. We are in the process of applying for MTLs in remaining states in the United States, an Electronic Money Institution (EMI) license in the EU, a fund transfer service license and a stablecoin license in Japan, a major payment institution license in Singapore and a money service operator license in Hong Kong; and we expect to upgrade the qualification as a Crypto Asset Service Provider, or CASP, under Markets in Crypto-Assets Regulation (MiCAR) in the EU. We also plan to further expand to Brazil, Argentina and other markets in South America where we could provide virtual asset services without being subject to licensing requirements. We believe our payment business powered by blockchain technology will be the most significant driver of our future business expansion plans. Our OwlPay services have historically been focused on processing transactions in fiat currencies, and no revenues for the years ended December 31, 2023 and December 31, 2024 were generated from OwlPay Harbor and OwlPay Wallet Pro. As we continue to roll out OwlPay Harbor and OwlPay Wallet Pro and expect market adoption of stablecoins to increase, we believe OwlPay Harbor and OwlPay Wallet Pro would enhance the breadth of our OwlPay services and strengthen our market position in digital asset payment solutions. We further believe our expansion into new products and markets from our current customer-centric businesses will enable us to capture cross-selling opportunities with our existing relationships in the e-commerce and hospitality industries, and to grow into a comprehensive cross-border payment solution suite and business ecosystem. For the year ended December 31, 2024, our company’s total revenue was comprised of our operations in the following main business segments: (i) Payments contributed to 53% of our total revenue; (ii) Hospitality (which include software services and platform services) contributed to 37% of our total revenue; and (iii) E-commerce contributed to 10% of our total revenue. Obook Holdings Inc. is located in Taipei City, Taiwan, Republic of China.
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
Doximity (DOCS - Free Report) closed the most recent trading day at $21.52, moving -3.11% from the previous trading session. This change lagged the S&P 500's 1.01% loss on the day. Elsewhere, the Dow saw a downswing of 0.77%, while the tech-heavy Nasdaq depreciated by 1.4%.
The medical social networking site's stock has climbed by 8.55% in the past month, exceeding the Medical sector's gain of 5.37% and the S&P 500's gain of 0.32%.
The investment community will be paying close attention to the earnings performance of Doximity in its upcoming release. The company is slated to reveal its earnings on August 6, 2026. In that report, analysts expect Doximity to post earnings of $0.29 per share. This would mark a year-over-year decline of 19.44%. Meanwhile, the latest consensus estimate predicts the revenue to be $151.7 million, indicating a 3.97% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $1.39 per share and revenue of $670.18 million, which would represent changes of -8.55% and +3.93%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Doximity is currently a Zacks Rank #3 (Hold).
In the context of valuation, Doximity is at present trading with a Forward P/E ratio of 15.93. This valuation marks a discount compared to its industry average Forward P/E of 27.82.
Meanwhile, DOCS's PEG ratio is currently 4.15. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 3.15.
The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.
Key Takeaways DOCS is expanding AI with rising physician use and early AI Search contracts with top-20 pharma companies.Doximity's Clinical AI Suite now serves 140 health systems, supporting retention and cross-selling.DOCS expects AI investment to trim margins as regulatory reviews delay meaningful revenue contribution. Doximity (DOCS - Free Report) is entering a pivotal phase as it accelerates investments in artificial intelligence to expand beyond its core physician engagement platform. While robust physician adoption, growing enterprise AI deployments and exceptional cash generation strengthen its long-term outlook, a sluggish pharma advertising market, rising AI investments and commercialization risks could temper near-term financial performance.
Shares of this Zacks Rank #3 (Hold) company have lost 49.8% so far this year compared with the industry's 5.6% decline and the S&P 500 Index’s 10.9% rise.
Doximity, with a market capitalization of $4.07 billion, is a global specialty medical device company.
DOCS’ bottom line is estimated to improve 3.8% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.99%.
Image Source: Zacks Investment Research
What's Driving DOCS’ Performance?AI Platform Is Rapidly Becoming Doximity's Next Major Growth Engine: Doximity is positioning artificial intelligence as its largest long-term monetization opportunity. Since acquiring Pathway, AI Search and AI Scribe users have tripled, while nearly half of all active prescribers now use the company's AI tools.
Management has already signed its first AI Search contracts with top-20 pharmaceutical companies and believes AI Search alone represents a multibillion-dollar incremental addressable market beyond its existing pharma advertising business. The combination of physician engagement, hospital adoption and early customer interest suggests Doximity is building a differentiated AI ecosystem that could materially expand revenues over the next several years rather than simply enhancing existing products.
Deepening Health System Integration: Doximity's growing integration into hospital workflows is making its platform increasingly indispensable to physicians. Nearly half of all U.S. doctors now work at health systems using Doximity's workflow or scheduling tools, while 140 health systems, including seven of the top 20 U.S. hospitals, have adopted its Clinical AI Suite.
Management emphasized that more than 250,000 prescribers now access AI capabilities through HIPAA-compliant enterprise deployments, creating a significant barrier for competitors. As hospitals increasingly prioritize secure AI environments over public AI tools, Doximity's trusted infrastructure, physician network and enterprise relationships should support higher customer retention and expanding cross-selling opportunities across workflow, telehealth and AI solutions.
Record Physician Engagement: Doximity continues to strengthen the core asset underpinning its business — physician engagement. Workflow usage increased approximately 30% year over year, reaching more than 800,000 quarterly active prescribers, representing one of the strongest engagement accelerations in the company's history. AI usage is growing even faster, with users nearly doubling their monthly query activity since January.
Higher engagement not only strengthens customer loyalty but also increases the value of Doximity's advertising, workflow and AI offerings to pharmaceutical companies and health systems. Management believes sustained engagement growth will eventually translate into stronger revenue expansion, particularly as new AI-powered commercial products become more widely adopted across its physician network.
What’s Weighing on DOCS Stock?Core Pharma Advertising Market Remains Weak: The biggest near-term challenge for Doximity remains the soft healthcare professional (HCP) digital advertising market. Management acknowledged continued policy uncertainty, macroeconomic risks and shorter pharmaceutical budgeting cycles, causing many customers to delay spending commitments and favor shorter-duration contracts.
The company expects the overall HCP digital advertising market to grow only around 5% or less during fiscal 2027, significantly below historical levels. Although Doximity continues to outperform many peers, sluggish industry spending limits visibility and reduces opportunities for traditional advertising growth. Until pharmaceutical companies regain confidence and commit to longer-term marketing budgets, revenue acceleration is likely to remain constrained.
AI Monetization Will Pressure Margins: While AI represents Doximity's largest long-term opportunity, management expects fiscal 2027 to be an investment year rather than a significant earnings contributor. The company plans to substantially increase spending on AI compute, engineering talent, brand marketing, and product development, resulting in adjusted EBITDA margins declining from 55% in fiscal 2026 to approximately 49% in fiscal 2027.
Management also expects minimal AI revenue contribution during the first half because regulatory reviews and customer implementation timelines will delay commercialization. Consequently, the company could face a period of elevated expenses without commensurate revenue growth, increasing execution risk if AI adoption progresses more slowly than anticipated.
Commercial Success Depends on Regulatory and Customer Adoption of AI: Although customer interest in AI Search appears strong, commercialization remains at a very early stage. Management acknowledged that pharmaceutical companies must complete extensive medical, legal and regulatory reviews before campaigns can be deployed, creating longer implementation timelines than traditional advertising products.
Because Doximity launched the commercial offering only recently, management expects most of the financial benefits to materialize in the second half of fiscal 2027. Delays in regulatory approvals, customer onboarding, or campaign execution could defer revenue recognition. Given management's expectation that AI Search will become a major future growth driver, slower-than-expected commercialization would likely weigh on investor expectations.
Estimate TrendThe Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $670.2 million, implying growth of 3.9% from the year-ago reported figure. The consensus mark for adjusted EPS is pinned at $1.39, indicating a decline of 8.6% from the previous year’s recorded level.
In the past 60 days, DOCS’ earnings estimate for fiscal 2027 has remained stable.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Alcon (ALC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alcon reported first-quarter 2026 earnings per share of 85 cents, which beat the Zacks Consensus Estimate by 6.3%. Revenues of $2.69 billion surpassed the Zacks Consensus Estimate by 0.3%.
Alcon has an estimated long-term earnings growth rate of 11.5%. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 3.66%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%.
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before.
Doximity Ask outranked OpenEvidence, GPT-5.6 Sol, Claude Fable 5, and other frontier models
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Doximity Ask, its HIPAA-compliant clinical AI platform, outperformed leading frontier AI models in the NOHARM (Numerous Options Harm Assessment for Risk in Medicine) benchmark, one of the most comprehensive independent evaluations of clinical AI safety to date.
The study, conducted by ARISE, a clinical AI research team led by physicians from Stanford and Harvard Medical Schools, evaluated how AI models perform when researchers prompted them with simulated patient cases.
Doximity Ask ranked first among all AI systems evaluated on the study's real-world clinical sample, the portion of the benchmark that most closely mirrors how physicians use these tools in practice. Across the broader automated evaluation, purpose-built clinical AI systems outperformed general-purpose frontier models by a wide margin.
Why Doximity Ask Outperformed
Doximity Ask is a HIPAA-compliant AI assistant built specifically for clinical workflows.
Our performance traces directly to our investment in physician authorship at scale. Through our PeerCheck™ program, more than 11,000 cited physician experts have evaluated and improved Doximity Ask outputs.
"We have long believed that the path to trustworthy healthcare AI runs through physicians, not around them," said Dr. Louis-Antoine Mullie, Head of Medical AI at Doximity. "Continuous physician review isn't a differentiator. It's a requirement. This result reinforces the importance of combining advanced AI systems with rigorous clinical oversight and independent safety evaluations like NOHARM."
Doximity's Clinical AI Suite, including Ask, has been reviewed, approved, and deployed across more than 150 health systems, including eight of the nation's top 20 hospitals.
The platform includes end-to-end encryption, role-based access controls, audit logging, and session isolation to help healthcare organizations deploy AI while maintaining enterprise-grade security and privacy standards.
To learn more about Doximity Ask, visit www.doximity.com.
Read more about the study methodology on the Doximity blog.
Notes to Editors:
For the full study, please click here. The chart on the left shows how the top U.S. models performed on F1 score, which balances precision and recall, before the cases and answers were made public. The chart on the right shows automated testing across more than 1,100 scenarios spanning 10 medical specialties. The benchmark was developed by more than 50 researchers with contributions from 29 board-certified physicians. About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.
Doximity (DOCS - Free Report) ended the recent trading session at $21.77, demonstrating a -1.09% change from the preceding day's closing price. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, added 0.29%.
Coming into today, shares of the medical social networking site had gained 9.94% in the past month. In that same time, the Medical sector gained 5.6%, while the S&P 500 gained 2.2%.
The investment community will be paying close attention to the earnings performance of Doximity in its upcoming release. The company is predicted to post an EPS of $0.29, indicating a 19.44% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $151.7 million, up 3.97% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.39 per share and a revenue of $670.18 million, signifying shifts of -8.55% and +3.93%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Doximity presently features a Zacks Rank of #5 (Strong Sell).
Valuation is also important, so investors should note that Doximity has a Forward P/E ratio of 15.79 right now. This valuation marks a discount compared to its industry average Forward P/E of 27.63.
Investors should also note that DOCS has a PEG ratio of 4.11 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 3.16.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 157, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
If you currently own Doximity stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
In the latest trading session, Doximity (DOCS - Free Report) closed at $19.85, marking a -4.7% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq decreased by 0.46%.
Shares of the medical social networking site witnessed a gain of 2.81% over the previous month, trailing the performance of the Medical sector with its gain of 2.92%, and outperforming the S&P 500's loss of 1.4%.
Market participants will be closely following the financial results of Doximity in its upcoming release. The company is expected to report EPS of $0.29, down 19.44% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $151.7 million, up 3.97% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.39 per share and a revenue of $670.18 million, indicating changes of -8.55% and +3.93%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Doximity. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Doximity possesses a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Doximity is holding a Forward P/E ratio of 15. This indicates a discount in contrast to its industry's Forward P/E of 25.92.
It is also worth noting that DOCS currently has a PEG ratio of 2.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 1.96.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 167, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.”
On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.”
On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Doximity (DOCS - Free Report) ended the recent trading session at $20.89, demonstrating a +1.02% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The stock of medical social networking site has risen by 5.62% in the past month, leading the Medical sector's gain of 4.28% and the S&P 500's gain of 2.14%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.29, signifying a 19.44% drop compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $151.7 million, indicating a 3.97% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.39 per share and a revenue of $670.18 million, representing changes of -8.55% and +3.93%, respectively, from the prior year.
Any recent changes to analyst estimates for Doximity should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Doximity boasts a Zacks Rank of #5 (Strong Sell).
From a valuation perspective, Doximity is currently exchanging hands at a Forward P/E ratio of 14.89. This represents a discount compared to its industry average Forward P/E of 24.48.
It is also worth noting that DOCS currently has a PEG ratio of 2.12. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. DOCS's industry had an average PEG ratio of 1.89 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 173, positioning it in the bottom 30% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DOCS in the coming trading sessions, be sure to utilize Zacks.com.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
A month has gone by since the last earnings report for Doximity (DOCS - Free Report) . Shares have added about 11.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Doximity due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Doximity, Inc. before we dive into how investors and analysts have reacted as of late.
Doximity Q3 Earnings & Revenues Beat EstimatesDoximity delivered adjusted earnings per share (EPS) of 46 cents in the third quarter of fiscal 2026, which increased 2.2% year over year. The figure surpassed the Zacks Consensus Estimate by 4.5%.
GAAP EPS for the quarter was 31 cents, reflecting a downtick of 16.2% from the year-ago figure.
DOCS’ Q3 Revenues in DetailDoximity registered revenues of $185.1 million in the fiscal third quarter, up 10% year over year. The figure surpassed the Zacks Consensus Estimate by 2.3%.
Doximity’s Segment DetailsDoximity derives revenues from two sources: Subscription and Other.
In the third quarter of fiscal 2026, Subscription revenues totaled $175.4 million, up 8.1% year over year. This was driven by stronger spend from existing customers, reflected in a 112% net revenue retention rate and growth in large accounts, with 126 customers contributing over $500,000 and representing 84% of revenues.
The Other revenues totaled $9.7 million, up 52.6% year over year.
DOCS’ Margin TrendIn the quarter under review, Doximity’s gross profit rose 7.7% year over year to $166.4 million. However, the gross margin contracted 170 basis points (bps) to 89.9%.
Sales and marketing expenses increased 9.6% year over year to $42.2 million, and research and development expenses rose 54.3% year over year to $34.6 million. General and administrative expenses increased 29.9% year over year to $17.7 million. Total operating expenses of $94.5 million rose 26.8% year over year.
The operating profit totaled $71.9 million, reflecting a 10% downtick from the prior-year quarter. The operating margin in the fiscal third quarter contracted 855 bps to 38.9%.
Doximity’s Financial PositionDoximity exited third-quarter fiscal 2026 with cash and cash equivalents of $64.8 million compared with $169.2 million at the fiscal second-quarter end.
Cumulative net cash provided by operating activities at the end of third-quarter fiscal 2026 was $216.9 million compared with $174.8 million a year ago.
DOCS’ Guidance for Q4 & FY26Doximity has provided its financial outlook for the fourth quarter of fiscal 2026 and updated its outlook for the full fiscal year.
For the fiscal fourth quarter, the company expects revenues in the range of $143 million-$144 million.
DOCS now projects its full fiscal year revenues between $642.5 million and $643.5 million, compared to the prior outlook of $640 million-$646 million.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -31.3% due to these changes.
VGM ScoresCurrently, Doximity has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Doximity has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerDoximity is part of the Zacks Medical Info Systems industry. Over the past month, Hims & Hers Health, Inc. (HIMS - Free Report) , a stock from the same industry, has gained 19.1%. The company reported its results for the quarter ended March 2026 more than a month ago.
Hims & Hers Health reported revenues of $608.1 million in the last reported quarter, representing a year-over-year change of +3.8%. EPS of -$0.18 for the same period compares with $0.20 a year ago.
For the current quarter, Hims & Hers Health is expected to post a loss of $0.02 per share, indicating a change of -111.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Hims & Hers Health has a Zacks Rank #5 (Strong Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful multi-year execution path can plausibly deliver triple-digit returns. The $50 ceiling is the filter; the AI flywheel is the thesis.
With that in mind, here are seven healthcare AI stocks trading under $50 where the bull case is grounded in product, partnership, or platform data, not hype.
Tempus AI Tempus AI (NASDAQ: TEM | TEM Price Prediction) pairs genomic diagnostics with a massive healthcare data library that pharma partners license for AI-driven drug discovery. At around $43.93, shares are down 25.6% year to date and are well below the $67.20 analyst target price, with 10 Buy or Strong Buy ratings against one Sell.
Q4 2025 revenue grew 83% year over year to $367.21 million, adjusted EBITDA flipped positive at $12.89 million, and 2026 guidance calls for $1.59 billion in revenue and roughly $65 million in adjusted EBITDA. CEO Eric Lefkofsky said “network effects from our investments in AI continue to compound,” backed by deepening partnerships with Gilead, Merck, and Daiichi Sankyo. The risk is that an accumulated deficit of $2.4 billion, heavy stock-based comp, and the $460 million in convertible notes priced in May 2026 add dilution and execution risk. Still, the data flywheel keeps spinning.
Hims & Hers Health Hims & Hers Health (NYSE: HIMS) runs a direct-to-consumer telehealth platform that uses AI to personalize care across weight loss, dermatology, mental health, and sexual wellness. At about $25.05 a share, the stock is down 57.2% over one year, with a forward P/E near 48x.
FY2026 guidance was raised to $2.80 billion to $3.00 billion in revenue and $275 million to $350 million in adjusted EBITDA, and management is targeting $6.5 billion in revenue and $1.3 billion adjusted EBITDA by 2030. International revenue surged 969% to $78.19 million, and a $250 million buyback was authorized. CEO Andrew Dudum called 2026 “a defining year.” The bull case is based on subscriber growth, the Novo Nordisk branded GLP-1 partnership, and international scaling. Notably, Q1 2026 EPS missed consensus estimates by 396.74%, U.S. revenue declined, and ongoing FDA and securities lawsuits around compounded GLP-1s remain unresolved.
Doximity Doximity (NYSE: DOCS) operates the dominant professional network for U.S. physicians, now layered with Doximity GPT and clinical AI workflow tools. Trading at around $18.97, the stock is down 57.2% year to date, with a PEG ratio of 0.715 and a forward P/E near 16x.
The platform now reaches 800,000+ active prescribers, with nearly half using clinical AI and prompts per user nearly doubling between January and April 2026. FY2026 generated $644.86 million in revenue, $196.05 million in net income, and $317.50 million in free cash flow, and the company repurchased $431.7 million of stock. The triple-digit upside thesis depends on AI engagement converting into pharma ad pricing power. The risk here is that FY2027 revenue guidance of $664 million to $676 million implies meaningful growth deceleration, and stock-based comp doubled. The cash generation cushions the multi-year story.
Nurix Therapeutics Nurix Therapeutics (NASDAQ: NRIX) applies an AI and computational platform to targeted protein degradation, a next-generation drug modality. At about $15.86, shares are well below the $30.18 analyst target, with 17 Buy or Strong Buy ratings and zero Holds or Sells.
Lead asset bexobrutideg, a BTK degrader, is enrolling the Phase 2 DAYBreak CLL-201 study, with Phase 3 DAYBreak CLL-306 set to start mid-2026 and an IND submission planned in autoimmune indications. CEO Arthur Sands has positioned bex as a “potential best-in-class” CLL therapy. Active collaborations with Gilead, Sanofi, and Pfizer carry 50/50 U.S. profit-share opt-ins, and $540.73 million in cash may fund the runway through 2027 readouts. However, Q1 revenue collapsed 66.1% year over year as the Sanofi initial research term expired, and clinical trials can fail at any stage.
Schrödinger Schrodinger (NASDAQ: SDGR) combines physics-based simulation with AI in a drug discovery platform used by most major biopharma R&D groups. At around $11.95, the stock is down 33.2% year to date, with analysts targeting $20.88.
FY2026 guidance calls for ACV of $218 million to $228 million and drug discovery revenue of $55 million to $65 million, with the Bunsen agentic AI co-scientist launching in summer 2026. Lilly’s pending acquisition of co-founded Ajax Therapeutics for up to $2.3 billion validates the ecosystem; Schrodinger holds a 5.8% stake. CEO Ramy Farid said, “the biopharmaceutical funding environment is improving,” which matters since software revenue is mid-transition. Yet operating cash flow swung to negative $14.83 million from positive $144 million year over year, and cash burn is meaningful. If Bunsen lands, the multi-year setup is compelling.
Phreesia Phreesia (NYSE: PHR) sells AI-enabled patient intake and provider workflow software to thousands of healthcare practices. At about $8.77, the stock is down 65.9% over one year, with an analyst target of $15.39 and a forward P/E near 18x.
FY2026 delivered Phreesia’s first-ever positive GAAP net income year, with adjusted EBITDA above $100 million and free cash flow over $50 million. Q4 free cash flow set a record at $28.5 million, up 210%. CEO Chaim Indig said the “underlying platform is stronger than it has ever been.” The bull case is based on AI-driven margin expansion plus a depressed share price. Risk: FY2027 revenue guidance was cut to $510 million to $520 million on pharma manufacturer pullback in vaccines and GLP-1 categories, sending shares down roughly 25%. Profitability is durable; growth visibility is not.
AbCellera Biologics AbCellera Biologics (NASDAQ: ABCL) runs an AI and machine-learning antibody discovery platform, now also advancing its own internal pipeline. At around $4.09, the stock is up 102.5% over one year but well below the $10.14 analyst target, implying meaningful upside.
Q1 revenue grew 96.3% year over year to $8.31 million and EPS beat by 29%. Lead asset ABCL635, a non-hormonal antibody for vasomotor symptoms, posted positive Phase 1 interim data with about a 24-day half-life supporting monthly dosing; the addressable market is over $6 billion, with 12 million U.S. women suffering moderate-to-severe VMS. CEO Carl Hansen described the upcoming Q3 2026 Phase 2 readout as “highly de-risking,” followed by an ABCL575 Phase 1 readout in Q4 2026. With around $655 million in available liquidity, the balance sheet is strong. The risks are pre-revenue burn and binary trial outcomes.
The Takeaway A low share price by itself is never a reason to buy or avoid a stock. Each of these names carries real volatility, ongoing losses or dilution exposure, and execution risk that could materially change the thesis. Treat this list as a research starting point, dig into the latest filings, and size positions accordingly before acting.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching.
The Q1 2026 release on May 11, 2026 was a fracture. EPS came in at -$0.40 against a $0.03 consensus, a 1,266% miss, with a net loss of $92.11 million versus net income of $49.48 million a year earlier. GAAP gross margin compressed to 65% from 73%, and adjusted EBITDA collapsed to a 7% margin. The U.S. business, the actual core, shrank 8% year over year. Shares fell 14.1% on the day to $25.03, capping a 54.66% one-year decline.
The valuation remains stretched even after the drop. Even after the fall, Hims trades at a trailing P/E of 57 and a forward P/E of 67, with an operating margin of -12.9%. Total liabilities ballooned 431% year over year to $1.82 billion, freighted with roughly $1 billion of convertible debt. The C-suite has voted with its feet: CEO Andrew Dudum disposed of 436,190 shares at $24.77 on April 13, and the CFO, COO, and Chief Legal Officer all dumped stock in the weeks before the earnings release.
The Redirect: A Profitable Physician Network The smarter rotation is Doximity (NYSE:DOCS | DOCS Price Prediction), the LinkedIn for U.S. physicians, now trading at $26.45 with a $3.54 billion market cap. Three reasons it deserves the attention HIMS is hogging.
One: real profits. Fiscal Q3 2026, reported February 5, 2026, delivered revenue of $185.05 million, up 9.8% year over year, with adjusted EBITDA of $111.40 million at a 60.2% margin and net income of $61.56 million. Compare that 60% margin to the 7% Hims just posted while burning $33 million on GLP-1 restructuring.
Two: platform engagement is compounding. Doximity now serves over 1 million quarterly active prescribers, 720,000 workflow users, and 300,000-plus AI product users, with AI Scribe and DoxGPT growing 50% quarter over quarter. That is durable, sticky physician utility, well removed from consumer GLP-1 churn at $80 a month with declining revenue per subscriber.
Three: capital discipline. The board authorized a $500 million share repurchase program. CEO Jeff Tangney summed it up plainly: “We’re proud to deliver another quarter of strong profits and record engagement.” Hims is issuing convertibles to fund acquisitions and stock-based comp. Doximity is buying its own shares back with cash from operations.
The peer set sharpens the point. Teladoc Health (NYSE:TDOC) still bleeds cash, with a $200 million FY2025 net loss and a stock down 94.9% over five years. Veeva Systems (NYSE:VEEV) is the blue-chip benchmark, profitable at a 28.4% profit margin, but already a $26 billion market cap. Doximity sits in the sweet spot: small enough to compound, profitable enough to defend.
For a retirement-focused portfolio, the lesson is the one this writer has watched play out a dozen times. Hype-cycle stocks lose 50% and still aren’t cheap. Cash-generative platforms with engagement moats are what survive the next downcycle. The wreckage at Hims warrants caution; Doximity belongs on the research list.
Dr Martens PLC (LSE:DOCS) shares stomped 6.5% higher to 68.5p as the bookmaker returned to profit growth last year, thanks to reduced discounting as part of a turnaround centred on higher-quality sales.
The FTSE 250-listed group reported an adjusted pre-tax profit of £55 million in the year to 29 March, up 61% on the year before, while revenue fell 2.9% to £764.9 million.
Gross margin increased to 66.2% from 65.0% as the company cut clearance activity across both its own stores and wholesale operations.
Shoes were the "current growth engine", with sales up 19%, while boots are "showing signs of stabilisation" as sales fell 8%, and bags remained "a long-term growth opportunity, with good early results" as sales grew 15%.
Group net debt excluding leases fell to £69.7 million from £94.1 million. The dividend was maintained at 2.55p.
The company has spent the past two years stabilising the business after weaker demand and excess inventory hurt profits, particularly in the US.
Management, led by chief executive Ije Nwokorie, is now shifting from a “channel-led” model to a “consumer-first” strategy, with greater focus on full-price sales, selective retail investment and wholesale partnerships.
Nwokorie, a former senior director in Apple's retail arm, said the group was now moving into the “scale phase” of the strategy in the new 2027 financial year, with a focus on retail store estate rather than opening new sites.
“There is still work to do in pivoting the business,” he said, adding that demand for the brand continued to strengthen, with growing interest from collaborators and wholesale partners.
The company said it expected “further strong” profit growth this year despite geopolitical uncertainty and weaker consumer confidence in some markets.
Analyst John Stevenson at Peel Hunt said PBT was ahead of his £52.3 million forecast, but also includes a restatement of the US tariff amount of circa £4 million, which leaves underlying PBT "broadly in line with our forecasts if we strip this out".
He noted "good progress" around the group, with US direct-to-consumer sales up 14%, wholesale back in growth and a "strong order book" for autumn/winter.
"There is a wide range to consensus, at £61-71 million FY27 PBT, with numbers likely to move towards the lower end, in our view, reflecting the challenging trading in EMEA."
** UPDATE: Adds share price and broker comments **
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:40 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties a.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Shares of the leading digital platform for medical professionals, Doximity (DOCS 1.14%), dropped again earlier in May after the company reported fourth-quarter earnings, and the stock is now down a staggering 56% in 2026.
The big issue on the market's mind is whether the company can survive the threat that AI's rise may pose to Doximity's operations. For instance, the company's Scribe product, which transcribes and generates notes during doctor visits, is a somewhat "common" feature in today's AI-powered world.
Similarly, its Ask solution is a large language model tailored for doctors -- but may not offer enough differentiation from the leading AI companies today.
Image source: Getty Images.
However, focusing solely on these software risks undermines Doximity's deeply entrenched ecosystem.
First, Doximity is used by more than 85% of U.S. physicians -- a massive network. Second -- and thanks to this access to doctors -- the company counts all of the top 20 pharmaceutical manufacturers as advertising customers. Third, Doximity also counts the top 20 hospitals and healthcare systems as customers, whether for advertising or for its workflow solutions (the potentially disruptive software mentioned earlier).
Simply put, I don't think AI can replicate Doximity's strong ecosystem. In fact, I'd argue that the revolutionary technology could actually make the company's platform even stronger as it continues to incorporate AI into many of its solutions. In the fourth quarter, roughly half of Doximity's 800,000 active prescribers utilizing its workflow solutions used an AI tool. Similarly, seven of the top 20 hospitals purchased the company's new clinical AI suite.
That said, margins dipped in Q4 as Doximity's costs rose amid its "AI investment year," so this is something investors need to focus on in upcoming quarters.
Today's Change
(
-1.14
%) $
-0.23
Current Price
$
20.01
Ultimately, I think the AI fears are overdone -- especially given that HIPAA compliance, strict regulations, and considerable legal ramifications make it incredibly difficult for a big tech company to just "vibe code" a better healthcare AI solution. Trading at just 15 times free cash flow (accounting for stock-based compensation and Doximity's $700 million cash balance), Doximity remains a top buy right now for me, as the cyclical pharma advertising industry should eventually rebound.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.”
On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Curious about Doximity's potential in the evolving healthcare tech landscape? Tune in as our experts rate its business strength and future growth prospects!
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.”
On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
If you currently own Doximity stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Doximity revealed its Q4 and full year 2026 financial results on May 13, 2026. The Company fell short of consensus estimates for full year revenue. The Company's CEO warned that increased investment in AI will "weigh on near-term margins." Based on this news, shares of Doximity fell by 23% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm PR Newswire
LOS ANGELES, June 8, 2026
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Doximity revealed its Q4 and full year 2026 financial results on May 13, 2026. The Company fell short of consensus estimates for full year revenue. The Company's CEO warned that increased investment in AI will "weigh on near-term margins." Based on this news, shares of Doximity fell by 23% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335 [email protected]
www.schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/docs-investors-have-opportunity-to-join-doximity-inc-fraud-investigation-with-the-schall-law-firm-302793532.html
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity’s management highlighted AI cost pressure, with the Company’s vice president of investor relations citing gross margin impact “driven by AI compute costs” and CEO Jeff Tangney warning that higher AI investment will “weigh on near-term margins.”
On this news, Doximity’s stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Doximity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Doximity issued a press release announcing its fourth quarter and fiscal year 2026 financial results. Among other items, Doximity guided for full-year revenue in the range of $664 million to $676 million, compared to estimates of $687.04 million, and adjusted EBITDA of $323 million to $335 million. Doximity's management highlighted AI cost pressure, with the Company's vice president of investor relations citing gross margin impact "driven by AI compute costs" and CEO Jeff Tangney warning that higher AI investment will "weigh on near-term margins."
On this news, Doximity's stock price fell $5.38 per share, or 23%, to close at $18.01 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or "the Company") (NYSE: DOCS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Doximity revealed its Q4 and full year 2026 financial results on May 13, 2026. The Company fell short of consensus estimates for full year revenue. The Company's CEO warned that increased investment in AI will "weigh on near-term margins." Based on this news, shares of Doximity fell by 23% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
